Implementing non-invasive RHD genotyping on cell-free foetal DNA from maternal plasma: The Pavia experience

Blood Transfusion

Volumn 10, Issue 1, 2012, Pages 34-38

  Sbarsi, Ilaria ^a   Isernia, Paola ^a   Montanari, Laura ^a   Badulli, Carla ^a   Martinetti, Miryam ^a   Salvaneschi, Laura ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Cell free foetal DNA; HDFN; Non invasive prenatal diagnosis; RHD genotyping; Validation protocol

Indexed keywords

GENOMIC DNA; PRIMER DNA; RHESUS D ANTIBODY;

ADULT; AMNION CELL; ARTICLE; BLOOD GROUP RH; BLOOD SAMPLING; CELL FREE SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FETUS; GENOTYPE; GESTATIONAL AGE; GOLD STANDARD; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MATERNAL PLASMA; NON INVASIVE PROCEDURE; PRENATAL DIAGNOSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; DNA; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; MALE; POLYMERASE CHAIN REACTION; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS; RH-HR BLOOD-GROUP SYSTEM;

EID: 84855744935     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2011.0021-11     Document Type: Article

References (16)

1. Westhoff CM. Molecular testing for transfusion medicine. Curr Opin Hematol 2006; 13: 471-5. (Pubitemid 44607450)
2. Daniels G, Finning K, Martin P, Soothill P. Fetal blood group genotyping from DNA from maternal plasma: an important advance in the management and prevention of haemolytic disease of the fetus and newborn. Vox Sang 2004; 87: 225-32. (Pubitemid 39627149)
3. Urbaniak SJ. The scientific basis of antenatal prophylaxis. Br J Obstet Gynaecol 1998; 105: 11-8. (Pubitemid 28528679)
4. Koelewijn JM, de Haas M, Vrijkotte TGM, et al. Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis. BJOG 2009; 116: 1307-14.
5. Engelfriet CP, Reesink HW, Judd WJ, et al. Current status of immunoprophylaxis with anti-D immunoglobin. Vox Sang. 2003; 85: 328-37. (Pubitemid 37522609)
6. Illanes S, Soothill P. Noninvasive approach for the management of haemolytic disease of the fetus. Expert Rev Hematol 2009; 2: 577-82.
7. Wilson RD. Amniocentesis and chorionic villus sampling. Curr Opin Obstet Gynecol 2000; 12: 81-6. (Pubitemid 32250635)
8. Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997; 350: 485-7. (Pubitemid 27343304)
9. Akolekar R, Finning K, Kuppusamy R, et al. Fetal RHD Genotyping in maternal plasma at 11-13 weeks of gestation. Fetal Diagn Ther 2011; 29: 301-6.
10. Finning KM, Martin PG, Soothill PW, et al. Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service. Transfusion 2002; 42: 1079-85.
11. Finning K, Martin P, Daniels G. A clinical service in the UK to predict fetal Rh (Rhesus) D blood group using free fetal DNA in maternal plasma. Ann N Y Acad Sci 2004; 1022: 119-23. (Pubitemid 38951591)
12. Avent ND, Reid ME. The Rh blood group system: a review. Blood 2000; 95: 375-87. (Pubitemid 30041644)
13. Singleton BK, Green CA, Avent ND, et al. The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in Africans with the Rh D-negative blood group phenotype. Blood 2000; 95: 12-8. (Pubitemid 30017219)
14. Daniels GL, Faas BH, Green CA, et al. The VS and V blood group polymorphisms in Africans: a serologic and molecular analysis. Transfusion 1998; 38: 951-8. (Pubitemid 28467224)
15. Lo YM, Tein MS, Lau TK, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet 1998; 62: 768-75 (Pubitemid 28194317)
16. Routine antenatal anti-D prophylaxis for women who are rhesus D negative. Review of NICE technology appraisal guidance 41. National Institute for Health and Clinical Excellence, London UK, August 2008.